Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • β-blocker
Beta-blocker Interruption Effects on Blood Pressure and Heart Rate After Myocardial Infarction: The AβYSS Trial
Posted inCardiology news Specialties

Beta-blocker Interruption Effects on Blood Pressure and Heart Rate After Myocardial Infarction: The AβYSS Trial

Posted by MedXY By MedXY 08/13/2025
This study assesses the impact of β-blocker interruption on blood pressure and heart rate following myocardial infarction, revealing significant increases associated with treatment cessation, particularly in hypertensive patients.
Read More
  • NT-501 Encapsulated Cell Therapy Successfully Slows Photoreceptor Loss in Macular Telangiectasia Type 2: Results from Two Phase 3 Trials
  • Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk
  • High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
  • IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
  • Post-PCI Troponin Kinetics Reveal Hemorrhagic Transformation as a Critical Driver of In-Hospital Mortality in STEMI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial SGLT2 inhibitors targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in